24 relations: Adenylyl cyclase, Adverse effect, Agonist, Allodynia, Analgesic, Benzothiophene, Binding selectivity, Drug tolerance, Eptapirone, Extracellular signal–regulated kinases, F-15,599, Flesinoxan, G alpha subunit, G protein, Laboratoires Pierre Fabre, Levodopa-induced dyskinesia, Neurolixis, Opioid, Parkinson's disease, Parkinson's UK, Potency (pharmacology), Receptor-mediated endocytosis, The Michael J. Fox Foundation, 5-HT1A receptor.
Adenylyl cyclase (also commonly known as adenyl cyclase and adenylate cyclase, abbreviated AC) is an enzyme with key regulatory roles in essentially all cells.
In medicine, an adverse effect is an undesired harmful effect resulting from a medication or other intervention such as surgery.
An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological response.
Allodynia (Ancient Greek άλλος állos "other" and οδύνη odúnē "pain") refers to central pain sensitization (increased response of neurons) following normally non-painful, often repetitive, stimulation.
An analgesic or painkiller is any member of the group of drugs used to achieve analgesia, relief from pain.
Benzothiophene is an aromatic organic compound with a molecular formula C8H6S and an odor similar to naphthalene (mothballs).
Binding selectivity is defined with respect to the binding of ligands to a substrate forming a complex.
Drug tolerance is a pharmacological concept describing subjects' reduced reaction to a drug following its repeated use.
Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family.
In molecular biology, extracellular signal–regulated kinases (ERKs) or classical MAP kinases are widely expressed protein kinase intracellular signalling molecules that are involved in functions including the regulation of meiosis, mitosis, and postmitotic functions in differentiated cells.
F-15,599, also known as NLX-101, is a very potent and highly selective 5-HT1A receptor full agonist.
Flesinoxan (DU-29,373) is a potent and selective 5-HT1A receptor partial/near-full agonist of the phenylpiperazine class.
Guanine nucleotide binding proteins (G proteins) are membrane-associated, heterotrimeric proteins composed of three subunits: alpha, beta, and gamma.
G proteins, also known as guanine nucleotide-binding proteins, are a family of proteins that act as molecular switches inside cells, and are involved in transmitting signals from a variety of stimuli outside a cell to its interior.
Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company.
Levodopa-induced dyskinesia is a form of dyskinesia associated with levodopa, used to treat Parkinson's disease.
Neurolixis is a biopharmaceutical company focused on novel drugs for the treatment of human central nervous system diseases.
Opioids are substances that act on opioid receptors to produce morphine-like effects.
Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.
Parkinson's UK is a Parkinson's research and support charity in the United Kingdom.
In the field of pharmacology, potency is a measure of drug activity expressed in terms of the amount required to produce an effect of given intensity.
Receptor-mediated endocytosis (RME), also called clathrin-mediated endocytosis, is a process by which cells absorb metabolites, hormones, other proteins – and in some cases viruses – by the inward budding of plasma membrane vesicles containing proteins with receptor sites specific to the molecules being absorbed (endocytosis).
The Michael J. Fox Foundation for Parkinson's Research is dedicated to finding a cure for Parkinson's disease (PD) through funded research and ensuring the development of improved therapies for those living with Parkinson's today.
The serotonin 1A receptor (or 5-HT1A receptor) is a subtype of serotonin receptor (5-HT receptor) that binds the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).